European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

1983 • 7,404 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Intensive Immunosuppression in Progressive Multiple Sclerosis

1983 • 813 citations

Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

1999 • 713 citations

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

1998 • 504 citations

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis

1999 • 490 citations

A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis

1987 • 465 citations

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

1996 • 444 citations

Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

2000 • 412 citations

Natural history of multiple sclerosis

1994 • 410 citations

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1993 • 378 citations

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

1991 • 373 citations

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1997 • 365 citations

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

1998 • 334 citations

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1997 • 280 citations

The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis

1995 • 251 citations

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1994 • 243 citations

Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation

1998 • 226 citations

Copolymer 1 acts against the immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1999 • 191 citations

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1991 • 176 citations

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1998 • 166 citations

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

1997 • 159 citations

Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS

2000 • 142 citations

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1996 • 105 citations

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

1997 • 105 citations

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1998 • 98 citations

The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections

1996 • 94 citations

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1992 • 81 citations

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis

1998 • 79 citations

Current immunotherapy in multiple sclerosis

1998 • 15 citations